In the original article, there was an error. **"Aspirin" was referred to instead of "TwHF."**

A correction has been made to **the last sentence of the Results section in the abstract**:

We screened 4137 abstracts for eligibility and included 594 studies in the analysis. The overall incidence of AEs was 26.7% (95% CI 24.8%, 28.8%) in 23,256 TwHF users. The estimates did vary markedly when stratified by specific study types. The incidence of gastrointestinal symptoms, adverse reproductive outcomes, adverse skin reactions, hematologic events and cardiovascular events were 13.3% (95% CI 11.9%, 14.9%), 11.7% (95% CI 10.3%, 13.3%), 7.8% (95% CI 6.3--9.5%), 6.5% (95% CI 5.7--7.4 %) and 4.9% (95% CI 1.6 %, 14.3 %), respectively. The prevalence of irregular menstruation (IM) was increased in patients taking TwHF compared with those given control (odds ratio \[OR\] 4.65, 95% CI 3.08 to 7.03). TwHF use has lower risk of weight gain (OR 0.12 \[95% CI 0.04 to 0.39\]) and hair loss (OR 0.37 \[95% CI 0.18 to 0.78\]). Furthermore, long-term TwHF use (\>6 months) has a higher AEs incidence (31.0% \[95% CI 24.5%--38.5%\]).

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.
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